With this financial support, AltroDomani Onlus and Parent Project Onlus associations contribute to EspeRare’s first sponsored clinical study conducted with Rimeporide in patients with DMD in Europe (RIM4DMD). This support will provide financial back up for the follow-up of patients who participate in this clinical trial in Italy and facilitate the organisation of the travel and accommodation of these patients and their families during their study visits at the hospital.
The RIM4DMD clinical study was initiated in June 2016 at the San Raffaele Hospital in Milano where Dr Stefano Previtali is the principal investigator. Recruitment at this site is ongoing.
The study is also open for recruitment in 3 other clinical centres in Europe: the Santa Creu i Sant Pau Hospital (Barcelona, Spain), the Armand Trousseau Hospital/ I-motion (Paris, France) and the Great Ormond Street Hospital (London, UK).
To find out more about EspeRare's RIM4DMD clinical project, please click here.
To find out more about AltroDomani Onlus, please click here.
To find out more about Parent Project Onlus, please click here. And to read this news on Parent Project Onlus' website, please click here.
As a private non-for-profit organisation, we strive to uncover the potential of existing molecules to address severe therapeutic unmet needs in rare diseases, thus giving better chances to existing drugs to reach these underserved patients.